METTL1P1

Across TCGA pan-cancer cohorts, METTL1P1 RNA differs between tumor and matched normal tissue in 7 of 18 cancer types tested, making tumor–normal expression one of METTL1P1’s most consistent transcriptional readouts.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where METTL1P1 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types METTL1P1 is over-expressed in tumor, although a few such as THCA show the opposite, repressed pattern.

HNSC, STAD, and BLCA are the cancer types where METTL1P1 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in METTL1P1 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
HNSC	All	All	+0.026	.013	4	view →
STAD	Male	All	+0.072	.001	2	view →
BLCA	All	All	+0.033	.045	2	view →
KIRC	All	III,IV	+0.033	.010	2	view →
COAD	All	All	+0.126	.041	1	view →
LUSC	Male	All	+0.029	.022	1	view →
THCA	All	All	−0.017	.027	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 7 strongest of 7 lineages.

METTL1P1–HNSC

Open the HNSC breakdown →